OVARIAN MUCINOUS ADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:30 UTC
-
Weekly chemo may improve outcomes for advanced ovarian cancer patients
Disease control OngoingThis study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Measles virus hijacks stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:50 UTC